Replimune Group (NASDAQ:REPL) Upgraded at Piper Sandler

Replimune Group (NASDAQ:REPL) was upgraded by Piper Sandler from a “hold” rating to a “strong-buy” rating in a report issued on Friday,Zacks.com reports.

Other analysts have also issued reports about the stock. BMO Capital Markets upgraded shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective for the company in a research note on Tuesday, June 30th. Wedbush upgraded shares of Replimune Group from a “neutral” rating to an “outperform” rating and increased their price target for the company from $9.00 to $12.00 in a report on Friday. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.29.

Replimune Group Trading Up 107.0%

NASDAQ REPL opened at $11.20 on Friday. Replimune Group has a 12 month low of $1.50 and a 12 month high of $12.50. The stock has a market cap of $941.14 million, a P/E ratio of -3.31 and a beta of 0.86. The stock’s fifty day moving average price is $9.49 and its 200-day moving average price is $7.38. The company has a current ratio of 4.79, a quick ratio of 4.79 and a debt-to-equity ratio of 0.63.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Monday, June 29th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, equities analysts forecast that Replimune Group will post -2.44 EPS for the current fiscal year.

Insider Activity

In other news, insider Christopher Sarchi sold 12,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Institutional Trading of Replimune Group

Several hedge funds have recently modified their holdings of the company. International Assets Investment Management LLC purchased a new stake in Replimune Group in the 4th quarter worth about $29,000. CWM LLC raised its holdings in shares of Replimune Group by 248.6% in the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the period. Essential Partners LLC lifted its stake in shares of Replimune Group by 562,400.0% during the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares during the last quarter. BNP Paribas Financial Markets grew its position in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Replimune Group in the second quarter worth $69,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

More Replimune Group News

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: The FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee backed results from the IGNYTE trial of RP1 (vusolimogene oderparepvec) combined with nivolumab for advanced melanoma patients whose disease progressed after anti-PD-1 therapy. The panel considered the evidence and clinical benefit meaningful despite concerns about the trial design. Replimune surges after FDA advisers back skin cancer drug
• Positive Sentiment: The 10-3 vote was widely viewed as a favorable regulatory signal, with analysts describing the panel outcome as overwhelmingly positive and suggesting that RP1’s approval prospects have improved. REPL Stock Tracks Best Day Ever
• Positive Sentiment: Replimune formally announced the favorable committee outcome for its resubmitted Biologics License Application, giving investors a clearer path toward a potential commercial product. Replimune Announces Favorable Outcome of FDA Advisory Committee Meeting

About Replimune Group

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.